• Explore /
  • Poster
  • / Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study).

Care 001: Multicenter randomized open label phase II trial of neoadjuvant trastuzumabemtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER 2 neu over-expressed breast cancer patients (TEAL study).

Abstract Poster

Authors

null

Tejal Amar Patel

Methodist Cancer Center, Houston, TX

Tejal Amar Patel , Joe Ensor Jr., Sarah Creamer , Angel Augusto Rodriguez , Polly Ann Niravath , Jorge German Darcourt , Virginia G. Kaklamani , Jane Lowe Meisel , Xiaoxian Li , John G. Kuhn , Roberto R Rosato , Anna Belcheva , Toniva Boone , Jenny Chee Ning Chang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02073487

Citation

J Clin Oncol 36, 2018 (suppl; abstr 581)

DOI

10.1200/JCO.2018.36.15_suppl.581

Abstract #

581

Poster Bd #

73

Abstract Disclosures

Similar Posters

First Author: Nadia Harbeck

First Author: Tejal Amar Patel

First Author: Sayeh Moazami Lavasani

First Author: Sara M. Tolaney